Global Continuous Glucose Monitoring Systems Market Research Report Information by Product, By Application, By End User, by Region Forecast till 2032

Description

List of Tables

Global Continuous Glucose Monitoring Systems Market Research Report Information by Product (Sensors, And Transmitter and Receivers), By Application (Type 2, Type 1, Non-diabetic Patients), By End User (Hospitals & Clinics, Homecare Settings, And Others), by Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032

Market Outlook

USD 8.8 billion in continuous glucose monitoring systems market value in 2023 With a compound annual growth rate (CAGR) of 12.34% for the forecast period (2024 - 2032), the market for Continuous Glucose Monitoring Systems is expected to rise from USD 10.0 Billion in 2024 to USD 25.8 billion by 2032.

One very notable factor driving the expansion of the Continuous Glucose Monitoring Systems Market is the rising global diabetes prevalence. With an amazing global increase in affected individuals, diabetes now reaches pandemic proportions. The International Diabetes Federation (IDF) estimates that 537 million people globally will be living with diabetes in 2021 and that figure is predicted to rise to 643 million by 2030. Likewise, the American Diabetes Association estimates that in 2021 diabetes will afflict 38.4 million Americans, or 11.6% of the population. About 2.0 million Americans, including some 304,000 children and teenagers, have type 1 diabetes. Among the several causes of the rising diabetes incidence include aging population, poor eating habits, and inactive lifestyles. The need of efficient diabetes care solutions gets more urgent as the diabetic population keeps rising.

Insights about Market Segments

Based on product, the segmentation of the Continuous Glucose Monitoring Systems Market divides sensors and transmitter and receivers.

Application that comprises type 2 diabetes, type 1 diabetes, and non-diabetic patients forms the basis of the market segmentation.

End users ranging from hospitals and clinics to homecare environments and others form the basis of the market segmentation.

Regional Insights

The report groups the market by Region: North America, Europe, Asia-Pacific, and the Rest of the World. America North-West With a market share of the highest 2023 constant glucose monitoring systems The strong technological infrastructure is the reason behind this; so, it is envisaged that the market would be driven by a well-established regulatory framework.

Thanks to rising diabetes prevalence in Europe and developments in CGM technology, Europe Continuous Glucose Monitoring Systems market holds second-largest market share. Furthermore, the Rest of Europe Continuous Glucose Monitoring Systems market is predicted to fastest-growing market in the European area while France Continuous Glucose Monitoring Systems market was ascribed to hold the highest market share.

From 2023 to 2032, the Asia-Pacific Continuous Glucose Monitoring Systems market is predicted to expand at a noteworthy proportion. This is a result of growing diabetes prevalence in the area and growing consciousness of diabetes control. Furthermore projected to have the biggest market share is China Continuous Glucose Monitoring Systems market; India Market for Continuous Glucose Monitoring Systems is predicted to develop fastest among Asia-Pacific countries.

The Middle East and Africa plus Latin America comprise the Rest of the World. Rising diabetes prevalence along with growing awareness of advanced glucose monitoring systems would probably cause the market for Continuous Glucose Monitoring Systems in the above stated areas to rise.

Leading Players

Key Companies in the Continuous Glucose Monitoring Systems Market are Dexcom, Inc. (US), Menarini Diagnostics SRL (Italy), Sensonics (US), Medtrum Technologies Inc. (China), Nemaura Medical Inc. (US), Ultrahuman Healthcare Pvt LTD (India), Medtronic (Ireland), One Drop (US), Abbott Laboratories, Inc. (US), Sinocare (China).

Product Code: MRFR/HC/18762-CR

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
- 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TECHNIQUE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 INCREASING PREVALENCE OF DIABETES
- 4.2.2 RISING AWARENESS AMONG INDIVIDUALS ABOUT THE BENEFITS OF CONTINUOUS GLUCOSE MONITORING AND PATIENT EDUCATION
- 4.2.3 INCREASING GERIATRIC POPULATION
4.3 RESTRAINTS
- 4.3.1 HIGH COST OF CONTINUOUS GLUCOSE MONITORING SYSTEMS
4.4 OPPORTUNITY
- 4.4.1 GROWING TECHNOLOGICAL ADVANCEMENTS AND INNOVATION

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION AND SALES
- 5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET
- 5.3.1 OVERVIEW

6 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY PRODUCT

6.1 OVERVIEW
6.2 SENSORS
6.3 TRANSMITTER & RECEIVERS

7 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY APPLICATION

7.1 OVERVIEW
7.2 TYPE 2 DIABETES
7.3 TYPE 1 DIABETES
7.4 NON-DIABETIC PATIENTS
- 7.4.1 WEIGHT LOSS
- 7.4.2 DIET MANAGEMENT
- 7.4.3 HEALTH & WELLNESS

8 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER

8.1 OVERVIEW
8.2 HOSPITALS & CLINICS
8.3 HOMECARE SETTINGS
8.4 OTHERS

9 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY REGION

9.1 GLOBAL
9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.2 CANADA
9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 FRANCE
- 9.3.3 UK
- 9.3.4 ITALY
- 9.3.5 SPAIN
- 9.3.6 REST OF EUROPE
9.4 ASIA-PACIFIC
- 9.4.1 CHINA
- 9.4.2 INDIA
- 9.4.3 JAPAN
- 9.4.4 SOUTH KOREA
- 9.4.5 AUSTRALIA
- 9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
- 9.5.1 MIDDLE EAST & AFRICA
- 9.5.2 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS,
10.3 COMPETITOR DASHBOARD
10.4 PUBLIC PLAYERS STOCK SUMMARY
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
- 10.6.2 AGREEMENT
- 10.6.3 PARTNERSHIP
- 10.6.4 COLLABORATION

11 COMPANY PROFILES

11.1 DEXCOM, INC
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
11.2 A. MENARINI DIAGNOSTICS SRL
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 KEY STRATEGIES
11.3 SENSEONICS
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 KEY STRATEGIES
11.4 MEDTRUM TECHNOLOGIES INC.
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 KEY STRATEGIES
11.5 NEMAURA MEDICAL INC.
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 SWOT ANALYSIS
- 11.5.6 KEY STRATEGIES
11.6 ULTRAHUMAN HEALTHCARE PVT LTD
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 KEY STRATEGIES
11.7 MEDTRONIC
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 SWOT ANALYSIS
- 11.7.6 KEY STRATEGIES
11.8 ONE DROP
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 SWOT ANALYSIS
- 11.8.6 KEY STRATEGIES
11.9 ABBOTT LABORATORIES, INC.
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 SWOT ANALYSIS
- 11.9.6 KEY STRATEGIES
11.10 SINOCARE
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 KEY STRATEGIES
11.11 NUTRISENSE
- 11.11.1 COMPANY OVERVIEW
- 11.11.2 FINANCIAL OVERVIEW
- 11.11.3 PRODUCTS OFFERED
- 11.11.4 KEY DEVELOPMENTS
- 11.11.5 KEY STRATEGIES
11.12 SUPERSAPIENS
- 11.12.1 COMPANY OVERVIEW
- 11.12.2 FINANCIAL OVERVIEW
- 11.12.3 PRODUCTS OFFERED
- 11.12.4 KEY DEVELOPMENTS
- 11.12.5 KEY STRATEGIES
11.13 SIGNOS INC.
- 11.13.1 COMPANY OVERVIEW
- 11.13.2 FINANCIAL OVERVIEW
- 11.13.3 PRODUCTS OFFERED
- 11.13.4 KEY DEVELOPMENTS
- 11.13.5 KEY STRATEGIES
11.14 LEVELS
- 11.14.1 COMPANY OVERVIEW
- 11.14.2 FINANCIAL OVERVIEW
- 11.14.3 PRODUCTS OFFERED
- 11.14.4 KEY DEVELOPMENTS
- 11.14.5 KEY STRATEGIES
11.15 VERI
- 11.15.1 COMPANY OVERVIEW
- 11.15.2 FINANCIAL OVERVIEW
- 11.15.3 PRODUCTS OFFERED
- 11.15.4 KEY DEVELOPMENTS
- 11.15.5 KEY STRATEGIES
11.16 LUMEN
- 11.16.1 COMPANY OVERVIEW
- 11.16.2 FINANCIAL OVERVIEW
- 11.16.3 PRODUCTS OFFERED
- 11.16.4 KEY DEVELOPMENTS
- 11.16.5 KEY STRATEGIES
11.17 JANUARY.AI
- 11.17.1 COMPANY OVERVIEW
- 11.17.2 FINANCIAL OVERVIEW
- 11.17.3 PRODUCTS OFFERED
- 11.17.4 KEY DEVELOPMENTS
- 11.17.5 KEY STRATEGIES

12 DATA CITATIONS